Pathological Mechanism and Targeted Drugs of COPD

References

• Rao W, Wang S, Duleba M, et al. Regenerative metaplastic clones in COPD lung drive inflammation and fibrosis. Cell. 2020;181(4):848–864. doi:10.1016/j.cell.2020.03.047
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou J, Wang J, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther. 2020;5(1):248. doi:10.1038/s41392-020-00345-x
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Burney PG, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076. doi:10.1038/nrdp.2015.76
   PubMed Web of Science ®Google Scholar
• Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009;18(114):213–221. doi:10.1183/09059180.00003609
   PubMedGoogle Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–743. doi:10.1016/S0140-6736(09)61303-9
   PubMed Web of Science ®Google Scholar
• Kume H, Hojo M, Hashimoto N. Eosinophil inflammation and hyperresponsiveness in the airways as phenotypes of COPD, and usefulness of inhaled glucocorticosteroids. Front Pharmacol. 2019;10:765. doi:10.3389/fphar.2019.00765
   PubMed Web of Science ®Google Scholar
• Benjamin JT, Plosa EJ, Sucre JM, et al. Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD. J Clin Invest. 2021;131(1):e139481. doi:10.1172/JCI139481
   PubMed Web of Science ®Google Scholar
• Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev. 2019;28(151):180063. doi:10.1183/16000617.0063-2018
   PubMed Web of Science ®Google Scholar
• Huang X, Mu X, Deng L, et al. The etiologic origins for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1139–1158. doi:10.2147/COPD.S203215
   PubMed Web of Science ®Google Scholar
• Nasri A, Foisset F, Ahmed E, et al. Roles of mesenchymal cells in the lung: from lung development to chronic obstructive pulmonary disease. Cells. 2021;10(12):3467. doi:10.3390/cells10123467
   PubMed Web of Science ®Google Scholar
• Kim HT, Yin W, Nakamichi Y, et al. WNT/RYK signaling restricts goblet cell differentiation during lung development and repair. Proc Natl Acad Sci U S A. 2019;116(51):25697–25706. doi:10.1073/pnas.1911071116
   PubMed Web of Science ®Google Scholar
• Berg K, Wright JL. The pathology of chronic obstructive pulmonary disease: progress in the 20th and 21st centuries. Arch Pathol Lab Med. 2016;140(12):1423–1428. doi:10.5858/arpa.2015-0455-RS
   PubMed Web of Science ®Google Scholar
• Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:995–1013. doi:10.2147/COPD.S82518
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219. doi:10.1183/13993003.01219-2018
   PubMed Web of Science ®Google Scholar
• Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging. 2008;25(5):415–443. doi:10.2165/00002512-200825050-00005
   PubMed Web of Science ®Google Scholar
• Tanabe N, Sato S, Muro S, et al. Regional lung deflation with increased airway volume underlies the functional response to bronchodilators in chronic obstructive pulmonary disease. Physiol Rep. 2019;7(24):e14330. doi:10.14814/phy2.14330
   PubMed Web of Science ®Google Scholar
• Chang RM, Kauffman RJ, Kwon Y. Understanding the paradigm shift to computational social science in the presence of big data. Decis Support Syst. 2014;63:67–80. doi:10.1016/j.dss.2013.08.008
   Web of Science ®Google Scholar
• Dang X, He B, Ning Q, et al. Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways. Respir Res. 2020;21(1):95. doi:10.1186/s12931-020-01358-4
   PubMed Web of Science ®Google Scholar
• Zhang MY, Jiang YX, Yang YC, et al. Cigarette smoke extract induces pyroptosis in human bronchial epithelial cells through the ROS/NLRP3/caspase-1 pathway. Life Sci. 2021;269:119090. doi:10.1016/j.lfs.2021.119090
   PubMed Web of Science ®Google Scholar
• Shih YM, Chang YJ, Cooke MS, et al. Alkylating and oxidative stresses in smoking and non-smoking patients with COPD: implications for lung carcinogenesis. Free Radic Biol Med. 2021;164:99–106. doi:10.1016/j.freeradbiomed.2020.12.442
   PubMed Web of Science ®Google Scholar
• Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature. 2014;505(7483):412–416. doi:10.1038/nature12807
   PubMed Web of Science ®Google Scholar
• Samsuzzaman M, Uddin MS, Shah MA, Mathew B. Natural inhibitors on airway mucin: molecular insight into the therapeutic potential targeting MUC5AC expression and production. Life Sci. 2019;231:116485. doi:10.1016/j.lfs.2019.05.041
   PubMed Web of Science ®Google Scholar
• Wu YF, Li ZY, Dong LL, et al. Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation. Autophagy. 2020;16(3):435–450. doi:10.1080/15548627.2019.1628536
   PubMed Web of Science ®Google Scholar
• Geramizadeh B, Jowkar Z, Karami L, Masoumpour M, Mehrabi S, Ghayoumi MA. Alpha-1 antitrypsin deficiency in Iranian patients with chronic obstructive pulmonary disease. Iran Red Crescent Med J. 2013;15(11):e7508. doi:10.5812/ircmj.7508
   PubMed Web of Science ®Google Scholar
• Rajendrasozhan S, Yao H, Rahman I. Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD. 2009;6(4):291-297..
   Google Scholar
• Sahakian E, Chen J, Powers JJ, et al. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. J Leukoc Biol. 2017;102(2):475–486. doi:10.1189/jlb.1A0415-176RRR
   PubMed Web of Science ®Google Scholar
• Zuo L, Wijegunawardana D. Redox role of ROS and inflammation in pulmonary diseases. Adv Exp Med Biol. 2021;1304:187–204.
   PubMed Web of Science ®Google Scholar
• Cui W, Zhang Z, Zhang P, et al. Nrf2 attenuates inflammatory response in COPD/emphysema: crosstalk with Wnt3a/β-catenin and AMPK pathways. J Cell Mol Med. 2018;22(7):3514–3525. doi:10.1111/jcmm.13628
   PubMed Web of Science ®Google Scholar
• Mizumura K, Maruoka S, Shimizu T, Gon Y. Role of Nrf2 in the pathogenesis of respiratory diseases. Respir Investig. 2020;58(1):28–35. doi:10.1016/j.resinv.2019.10.003
   PubMed Web of Science ®Google Scholar
• Fratta PA, Stranieri C, Ferrari M, et al. Oxidative stress and Nrf2 expression in peripheral blood mononuclear cells derived from COPD patients: an observational longitudinal study. Respir Res. 2020;21(1):37. doi:10.1186/s12931-020-1292-7
   PubMed Web of Science ®Google Scholar
• Genschmer KR, Russell DW, Lal C, et al. Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung. Cell. 2019;176(1–2):113–126. doi:10.1016/j.cell.2018.12.002
   PubMed Web of Science ®Google Scholar
• Mahor D, Kumari V, Vashisht K, et al. Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD. BMC Pulm Med. 2020;20(1):302. doi:10.1186/s12890-020-01323-3
   PubMed Web of Science ®Google Scholar
• Lu J, Xie L, Liu C, Zhang Q, Sun S. PTEN/PI3k/AKT regulates macrophage polarization in emphysematous mice. Scand J Immunol. 2017;85(6):395–405. doi:10.1111/sji.12545
   PubMed Web of Science ®Google Scholar
• Sun X, Chen L, He Z. PI3K/Akt-Nrf2 and anti-inflammation effect of macrolides in chronic obstructive pulmonary disease. Curr Drug Metab. 2019;20(4):301–304. doi:10.2174/1389200220666190227224748
   PubMed Web of Science ®Google Scholar
• Li N, Liu Y, Cai J. LncRNA MIR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease. Biomed Pharmacother. 2019;117:109015. doi:10.1016/j.biopha.2019.109015
   PubMed Web of Science ®Google Scholar
• Huang H, Feng H, Zhuge D. M1 macrophage activated by notch signal pathway contributed to ventilator-induced lung injury in chronic obstructive pulmonary disease model. J Surg Res. 2019;244:358–367. doi:10.1016/j.jss.2019.06.060
   PubMed Web of Science ®Google Scholar
• Takiguchi H, Yang CX, Yang C, et al. Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. Sci Rep. 2021;11(1):8282. doi:10.1038/s41598-021-87720-y
   PubMed Web of Science ®Google Scholar
• El-Gazzar AG, Kamel MH, Elbahnasy O, El-Naggar ME. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Expert Rev Respir Med. 2020;14(1):111–116. doi:10.1080/17476348.2019.1675517
   PubMed Web of Science ®Google Scholar
• Shyam PSB, Chaya SK, Kumar VS, et al. Inflammatory biomarkers interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α) are differentially elevated in tobacco smoke associated COPD and biomass smoke associated COPD. Toxics. 2021;9(4):72. doi:10.3390/toxics9040072
   PubMed Web of Science ®Google Scholar
• Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis. Am J Respir Crit Care Med. 2021;203(12):1488–1502. doi:10.1164/rccm.202009-3448OC
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Coccini T, Roda E, et al. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. Int J Chron Obstruct Pulmon Dis. 2018;13:1691–1700. doi:10.2147/COPD.S159915
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002;298(5596):1241–1245. doi:10.1126/science.1071914
   PubMed Web of Science ®Google Scholar
• Lee UJ, Choung SR, Prakash KV, et al. Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep. 2008;35(3):291–298. doi:10.1007/s11033-007-9084-4
   PubMed Web of Science ®Google Scholar
• Zhuan B, Yu Y, Yang Z, Li P, Li P. Mechanisms of oxidative stress effects of the NADPH oxidase-ROS-NF-κB transduction pathway and VPO1 on patients with chronic obstructive pulmonary disease combined with pulmonary hypertension. Eur Rev Med Pharmacol Sci. 2017;21(15):3459–3464.
   PubMed Web of Science ®Google Scholar
• Mojiri-Forushani H, Hemmati AA, Khodadadi A, et al. Valsartan attenuates bleomycin-induced pulmonary fibrosis by inhibition of NF-κB expression and regulation of Th1/Th2 cytokines. Immunopharmacol Immunotoxicol. 2018;40(3):225–231. doi:10.1080/08923973.2018.1431924
   PubMed Web of Science ®Google Scholar
• Balamayooran G, Batra S, Cai S, et al. Role of CXCL5 in leukocyte recruitment to the lungs during secondhand smoke exposure. Am J Respir Cell Mol Biol. 2012;47(1):104–111. doi:10.1165/rcmb.2011-0260OC
   PubMed Web of Science ®Google Scholar
• Starrett W, Blake DJ. Sulforaphane inhibits de novo synthesis of IL-8 and MCP-1 in human epithelial cells generated by cigarette smoke extract. J Immunotoxicol. 2011;8(2):150–158. doi:10.3109/1547691X.2011.558529
   PubMed Web of Science ®Google Scholar
• Kaur G, Batra S. Regulation of DNA methylation signatures on NF-κB and STAT3 pathway genes and TET activity in cigarette smoke extract-challenged cells/COPD exacerbation model in vitro. Cell Biol Toxicol. 2020;36(5):459–480. doi:10.1007/s10565-020-09522-8
   PubMed Web of Science ®Google Scholar
• Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543–550. doi:10.1016/j.ccell.2020.03.013
   PubMed Web of Science ®Google Scholar
• Yang G, Chang CC, Yang Y, et al. Resveratrol alleviates rheumatoid arthritis via reducing ROS and inflammation, inhibiting MAPK signaling pathways, and suppressing angiogenesis. J Agric Food Chem. 2018;66(49):12953–12960. doi:10.1021/acs.jafc.8b05047
   PubMed Web of Science ®Google Scholar
• Knobloch J, Jungck D, Kronsbein J, Stoelben E, Ito K, Koch A. LABAs and p38MAPK inhibitors reverse the corticosteroid-insensitivity of IL-8 in airway smooth muscle cells of COPD. J Clin Med. 2019;8(12):2058. doi:10.3390/jcm8122058
   PubMed Web of Science ®Google Scholar
• Banerjee A, Koziol-White C, Panettieri RJ. p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Curr Opin Pharmacol. 2012;12(3):287–292. doi:10.1016/j.coph.2012.01.016
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Sciacqua A, Terracciano R, Pelaia G. Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Rev Respir Med. 2020;14(5):485–491. doi:10.1080/17476348.2020.1732821
   PubMed Web of Science ®Google Scholar
• Keränen T, Moilanen E, Korhonen R. Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells. Inflamm Res. 2017;66(5):441–449. doi:10.1007/s00011-017-1028-4
   PubMed Web of Science ®Google Scholar
• Pinart M, Hussain F, Shirali S, et al. Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury. Eur J Pharmacol. 2014;744:108–114. doi:10.1016/j.ejphar.2014.10.003
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–635. doi:10.1016/j.cell.2017.07.029
   PubMed Web of Science ®Google Scholar
• Desale SE, Chidambaram H, Chinnathambi S. G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-βin Alzheimer’s disease. Mol Biomed. 2021;2(1):17. doi:10.1186/s43556-021-00036-1
   PubMedGoogle Scholar
• De la Cruz-Herrera CF, Baz-Martínez M, Lang V, et al. Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation. Oncogene. 2016;35(22):2873–2880. doi:10.1038/onc.2015.356
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang P, Zhang W, et al. PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits. Signal Transduct Target Ther. 2020;5(1):105. doi:10.1038/s41392-020-00218-3
   PubMed Web of Science ®Google Scholar
• An X, Wei Z, Ran B, et al. Histone deacetylase inhibitor trichostatin A suppresses cell proliferation and induces apoptosis by regulating the PI3K/AKT signalling pathway in gastric cancer cells. Anticancer Agents Med Chem. 2020;20(17):2114–2124. doi:10.2174/1871520620666200627204857
   PubMed Web of Science ®Google Scholar
• Mercado N, Thimmulappa R, Thomas CM, et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun. 2011;406(2):292–298. doi:10.1016/j.bbrc.2011.02.035
   PubMed Web of Science ®Google Scholar
• Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest. 2011;121(11):4289–4302. doi:10.1172/JCI45144
   PubMed Web of Science ®Google Scholar
• Aydemir Y, Aydemir Ö, Şengül A, et al. Comparison of oxidant/antioxidant balance in COPD and non-COPD smokers. Heart Lung. 2019;48(6):566–569. doi:10.1016/j.hrtlng.2019.07.005
   PubMed Web of Science ®Google Scholar
• Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118. doi:10.1378/chest.12-2357
   PubMed Web of Science ®Google Scholar
• Johnson K, Mcevoy CE, Naqvi S, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016;11:799–807. doi:10.2147/COPD.S102375
   PubMed Web of Science ®Google Scholar
• Li D, Shao R, Wang N, et al. Sulforaphane activates a lysosome-dependent transcriptional program to mitigate oxidative stress. Autophagy. 2021;17(4):872–887. doi:10.1080/15548627.2020.1739442
   PubMed Web of Science ®Google Scholar
• Wise RA, Holbrook JT, Criner G, et al. Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial. PLoS One. 2016;11(11):e163716. doi:10.1371/journal.pone.0163716
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhang C, Sun QY, et al. Infliximab protects against pulmonary emphysema in smoking rats. Chin Med J. 2011;124(16):2502–2506.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Flavin SK, Agarwal PK, Lo KH, Barnathan ES. Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Respir Med. 2013;107(3):424–432. doi:10.1016/j.rmed.2012.11.008
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469. doi:10.1164/rccm.200501-147OC
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–148. doi:10.1136/thoraxjnl-2012-202432
   PubMed Web of Science ®Google Scholar
• Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020;69(2):178–186. doi:10.1016/j.alit.2020.02.002
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):158–170. doi:10.1016/S2213-2600(19)30338-8
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023–1034. doi:10.1056/NEJMoa1905248
   PubMed Web of Science ®Google Scholar
• Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001–1011. doi:10.1164/rccm.201405-0992OC
   PubMed Web of Science ®Google Scholar
• Kuna P, Jenkins M, O’Brien CD, Ahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012;106(4):531–539. doi:10.1016/j.rmed.2011.10.020
   PubMed Web of Science ®Google Scholar
• Nordenmark LH, Taylor R, Jorup C. Feasibility of computed tomography in a multicenter COPD trial: a study of the effect of AZD9668 on structural airway changes. Adv Ther. 2015;32(6):548–566. doi:10.1007/s12325-015-0215-3
   PubMed Web of Science ®Google Scholar
• Navratilova Z, Kolek V, Petrek M. Matrix metalloproteinases and their inhibitors in chronic obstructive pulmonary disease. Arch Immunol Ther Exp. 2016;64(3):177–193. doi:10.1007/s00005-015-0375-5
   PubMed Web of Science ®Google Scholar
• Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169–177. doi:10.1016/j.pupt.2011.12.011
   PubMed Web of Science ®Google Scholar
• Ntontsi P, Detta A, Bakakos P, Loukides S, Hillas G. Experimental and investigational phosphodiesterase inhibitors in development for asthma. Expert Opin Investig Drugs. 2019;28(3):261–266. doi:10.1080/13543784.2019.1571582
   PubMed Web of Science ®Google Scholar
• Martin C, Burgel PR, Roche N. Inhaled dual phosphodiesterase 3/4 inhibitors for the treatment of patients with COPD: a short review. Int J Chron Obstruct Pulmon Dis. 2021;16:2363–2373. doi:10.2147/COPD.S226688
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-2018
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-7
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90. doi:10.2147/COPD.S89849
   PubMed Web of Science ®Google Scholar
• Lee SU, Sung MH, Ryu HW, et al. Verproside inhibits TNF-α-induced MUC5AC expression through suppression of the TNF-α/NF-κB pathway in human airway epithelial cells. Cytokine. 2016;77:168–175. doi:10.1016/j.cyto.2015.08.262
   PubMed Web of Science ®Google Scholar
• Li T, Wu YN, Wang H, Ma JY, Zhai SS, Duan J. Dapk1 improves inflammation, oxidative stress and autophagy in LPS-induced acute lung injury via p38MAPK/NF-κB signaling pathway. Mol Immunol. 2020;120:13–22. doi:10.1016/j.molimm.2020.01.014
   PubMed Web of Science ®Google Scholar
• Arora S, Dev K, Agarwal B, Das P, Syed MA. Macrophages: their role, activation and polarization in pulmonary diseases. Immunobiology. 2018;223(4–5):383–396. doi:10.1016/j.imbio.2017.11.001
   PubMed Web of Science ®Google Scholar
• Macnee W, Allan RJ, Jones I, Das P, Syed MA. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax. 2013;68(8):738–745. doi:10.1136/thoraxjnl-2012-202744
   PubMed Web of Science ®Google Scholar
• Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010;50(1):94–100. doi:10.1177/0091270009347873
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77. doi:10.1016/j.pupt.2017.08.008
   PubMed Web of Science ®Google Scholar
• Begg M, Hamblin JN, Jarvis E, et al. Exploring PI3Kδ molecular pathways in stable COPD and following an acute exacerbation, two randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2021;16:1621–1636. doi:10.2147/COPD.S309303
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Robertson J, et al. An inhaled PI3Kδ inhibitor improves recovery in acutely exacerbating COPD patients: a randomized trial. Int J Chron Obstruct Pulmon Dis. 2021;16:1607–1619. doi:10.2147/COPD.S309129
   PubMed Web of Science ®Google Scholar
• Fahy WA, Homayoun-Valiani F, Cahn A, et al. Nemiralisib in patients with an acute exacerbation of COPD: placebo-controlled, dose-ranging study. Int J Chron Obstruct Pulmon Dis. 2021;16:1637–1646. doi:10.2147/COPD.S309320
   PubMed Web of Science ®Google Scholar
• Rohrbacher L, Brauchle B, Ogrinc WA, von Bergwelt-Baildon M, Bücklein VL, Subklewe M. The PI3K∂-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression. Front Immunol. 2021;12:608625. doi:10.3389/fimmu.2021.608625
   PubMed Web of Science ®Google Scholar
• Kim RY, Pinkerton JW, Essilfie AT, et al. Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. 2017;196(3):283–297. doi:10.1164/rccm.201609-1830OC
   PubMed Web of Science ®Google Scholar
• Nachmias N, Langier S, Brzezinski RY, et al. NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation. PLoS One. 2019;14(5):e214622. doi:10.1371/journal.pone.0214622
   PubMed Web of Science ®Google Scholar
• Yang W, Ni H, Wang H, Gu H. NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease. Int J Clin Exp Pathol. 2015;8(10):13209–13216.
   PubMed Web of Science ®Google Scholar
• Wu X, Gong L, Xie L, et al. NLRP3 deficiency protects against intermittent hypoxia-induced neuroinflammation and mitochondrial ROS by promoting the PINK1-parkin pathway of mitophagy in a murine model of sleep apnea. Front Immunol. 2021;12:628168. doi:10.3389/fimmu.2021.628168
   PubMed Web of Science ®Google Scholar
• Yang H, Lv H, Li H, et al. Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways. Cell Commun Signal. 2019;17(1):62. doi:10.1186/s12964-019-0366-y
   PubMed Web of Science ®Google Scholar
• Li C, Zhihong H, Wenlong L, et al. The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 inflammasome regulates bronchial epithelial cell injury and proapoptosis after exposure to biomass fuel smoke. Am J Respir Cell Mol Biol. 2016;55(6):815–824. doi:10.1165/rcmb.2016-0051OC
   PubMed Web of Science ®Google Scholar